Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
Hyperlipidemia, hypertriglyceridemia in particular, is a common feature in patients with noninsulin dependent diabetes mellitus (NIDDM) and may associate with insulin insensitivity. Acipimox, being widely prescribed for treating hypertriglyceridemia, is also used in NIDDM patients for their dyslipidemia. In the present study, we evaluated the effect of acipimox in Chinese NIDDM patients with hypertriglyceridemia. A total of 16 patients enrolled in a double-blind, randomized, placebo-controlled and two-period crossover study. After an 8 week run-in period, patients were randomly assigned into two groups receiving either acipimox (250 mg, twice daily) or placebo treatment. A total of 12 weeks later, these two groups switched their treatment for an additional 12 weeks. Blood samples were collected at the end of the run-in period and then at 4-week intervals in the whole study for lipid profile. A modified insulin suppression test was performed at the ends of the run-in period, 12-week and 24-week treatment to assess changes in insulin sensitivity. Our results showed that acipimox significantly lowered serum total triglyceride while compared to those by placebo. However, no difference was observed in serum non-esterified fatty acid, low-density lipoprotein cholesterol, total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C) and HDL-C/ TC ratio between the two groups. Furthermore, glycemic indices and insulin sensitivity were similar during the base-line, placebo or acipimox periods. Taken together, our data suggest that acipimox significantly lowered TG without perturbation of insulin sensitivity in hypertriglyceridemic NIDDM patients.
Shih
K C
KC
Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC.
Kwok
C F
CF
Hwu
C M
CM
Hsiao
L C
LC
Li
S H
SH
Liu
Y F
YF
Ho
L T
LT
D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I / Q000032:analysis / Q000187:drug effects; D001055:Apolipoproteins B / Q000032:analysis / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications*; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000502:physiology; D008075:Lipoproteins, HDL / Q000032:analysis / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000032:analysis / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D014280:Triglycerides / Q000032:analysis / Q000097:blood
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D006442:Glycated Hemoglobin; D000960:Hypolipidemic Agents; D007328:Insulin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011719:Pyrazines; D014280:Triglycerides; C027696:acipimox